Article
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
Blood
(2014)
Disciplines
Publication Date
December 6, 2014
DOI
10.1182/BLOOD.V124.21.4679.4679
Citation Information
Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, Marshall T. Schreeder, et al.. "Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial" Blood Vol. 124 Iss. 21 (2014) p. 4679 - 4679 Available at: http://works.bepress.com/heather-brooks2/4/